New & Noteworthy!

ACC Rockies Chapter Please join our cardiology colleagues at the ACC Annual Meeting, a premier gathering of cardiovascular professionals from around the world. This dynamic conference brings together leading physicians, researchers, healthcare innovators, and industry experts to explore the latest advances in cardiovascular medicine. Attendees will experience cutting-edge clinical education, groundbreaking research presentations, interactive learning sessions, and exceptional networking opportunities focused on improving patient care and advancing the future of heart health.


For more information and to register, please visit: ACC Rockies Chapter Meeting 2026


ACC Live Courses
For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

RSS feed: Latest in Cardiology from ACC.org Latest in Cardiology from ACC.org

  • HFSA 2026: ATTRibute-CM Analysis; LINK-HF2 Results; More
    New science presented at HFSA 2026 and simultaneously published in JACC: Heart Failure spans several evolving areas in heart failure (HF), from ATTR-CM biomarkers and measures of physical function to predictors of adverse outcomes in transplant recipients to artificial intelligence (AI) wearables enhancing discharge care following HF hospitalization.
  • ACC-Supported Radiation Safety Coalition Seeks Clinician Input
    The ACC and the ALARA+ Coalition are seeking input from cardiovascular clinicians and health care facility administrators to help better understand the real-world impacts of occupational radiation exposure and inform future workplace safety efforts.
  • ACCEL Lite: TRANQUILITY: IL-6, An Important Mediator of CVD
    In this episode, Dipti Itchhaporia MD, MACC and Deepak L. Bhatt, MD, MPH, MBA, FACC discuss TRANQUILITY: Efficacy of monthly and quarterly dosing of pacibekitug (IL-6 ligand mAb) targeting inflammation in CKD with high cardiovascular risk.
  • CKM Syndrome: Insights From and Comparison of Recent Guidelines
    The 2026 ACC/AHA/Multisociety Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome provides an expanded framework for assessing and managing interconnected metabolic risk factors...
  • FDA Update: Agency Warns of Transcatheter MV Delivery System Issue
    The U.S. Food and Drug Administration (FDA) has issued an Early Alert, warning that Edwards Lifesciences is recommending certain delivery systems used for the SAPIEN M3 transcatheter mitral valve (MV) replacement be removed from use.